EverQuote Inc
For the period ended Dec 31, 2024. Filed Feb 25, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Feb 25, 2025
EVER$28.03-1.4%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 8. Consolidated Statements of Cash Flows
CONSOLIDATED STATEMENTS OF CASH FLOWS
(in thousands)
| Year Ended December 31, | |||
|---|---|---|---|
| 2024 | 2023 | 2022 | |
| Cash flows from operating activities: | |||
| Net income (loss) | $32,169 | $(51,287) | $(24,416) |
| Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities: | |||
| Depreciation and amortization expense | 5,672 | 6,196 | 5,848 |
| Stock-based compensation expense | 20,614 | 24,096 | 28,986 |
| Loss on sale of health assets | — | 19,388 | — |
| Impairment of right-of-use asset | — | 384 | — |
| Change in fair value of contingent consideration liabilities | — | (150) | (4,135) |
| Provision for bad debt | 13 | 204 | 693 |
| Unrealized foreign currency transaction (gains) losses | (26) | 21 | (9) |
| Changes in operating assets and liabilities: | |||
| Accounts receivable | (40,178) | 8,219 | 5,362 |
| Prepaid expenses and other current assets | 440 | 962 | (2,111) |
| Commissions receivable, current and non-current | 4,880 | 4,176 | (24,240) |
| Operating lease right-of-use assets | 2,213 | 2,497 | 2,613 |
| Other assets | (291) | 421 | (19) |
| Accounts payable | 42,664 | (13,411) | 1,124 |
| Accrued expenses and other current liabilities | 1,040 | (1,543) | (2,375) |
| Deferred revenue | (107) | 5 | (229) |
| Operating lease liabilities | (2,537) | (3,006) | (2,883) |
| Net cash provided by (used in) operating activities | 66,566 | (2,828) | (15,791) |
| Cash flows from investing activities: | |||
| Acquisition of property and equipment, including costs capitalized for development of internal-use software | (4,114) | (3,840) | (4,290) |
| Proceeds from sale of health assets | — | 13,194 | — |
| Net cash provided by (used in) investing activities | (4,114) | 9,354 | (4,290) |
| Cash flows from financing activities: | |||
| Proceeds from exercise of stock options | 3,553 | 979 | 942 |
| Proceeds from private placement of common stock | — | — | 15,000 |
| Tax withholding payments related to net share settlement | (1,846) | (402) | (100) |
| Net cash provided by financing activities | 1,707 | 577 | 15,842 |
| Effect of exchange rate changes on cash, cash equivalents and restricted cash | 1 | 18 | (27) |
| Net increase (decrease) in cash, cash equivalents and restricted cash | 64,160 | 7,121 | (4,266) |
| Cash, cash equivalents and restricted cash at beginning of period | 37,956 | 30,835 | 35,101 |
| Cash, cash equivalents and restricted cash at end of period | $102,116 | $37,956 | $30,835 |
| Supplemental disclosure of cash flow information: | |||
| Cash paid for income taxes | $2,336 | $589 | $175 |
| Supplemental disclosure of noncash investing and financing information: | |||
| Acquisition of property and equipment included in accounts payable | $135 | $25 | $60 |
| Issuance of Class A common stock to settle contingent consideration liabilities | $— | $— | $1,889 |
| Issuance of Class A common stock in settlement of stock-based compensation liability | $— | $— | $164 |
| Operating lease liabilities arising from obtaining right-of-use assets | $4,026 | $— | $1,096 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.